Cartesian Therapeutics (NASDAQ:RNAC) Releases Quarterly Earnings Results, Misses Estimates By $0.56 EPS

Cartesian Therapeutics (NASDAQ:RNAC) announced its quarterly earnings data on Monday. The company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.56), Zacks reports. The company had revenue of $0.95 million for the quarter, compared to analysts’ expectations of $0.10 million.

Cartesian Therapeutics Trading Down 7.9%

RNAC traded down $0.71 during midday trading on Tuesday, hitting $8.31. 197,806 shares of the company were exchanged, compared to its average volume of 189,250. The company’s 50 day simple moving average is $7.21 and its 200 day simple moving average is $8.17. The firm has a market capitalization of $216.01 million, a price-to-earnings ratio of -5.38 and a beta of 0.41. Cartesian Therapeutics has a 1-year low of $5.98 and a 1-year high of $18.80.

Insider Activity

In other news, CFO Blaine Davis sold 10,591 shares of the company’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $6.82, for a total value of $72,230.62. Following the sale, the chief financial officer owned 121,220 shares in the company, valued at $826,720.40. This represents a 8.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 60.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Wells Fargo & Company MN increased its holdings in Cartesian Therapeutics by 49.2% in the 4th quarter. Wells Fargo & Company MN now owns 11,762 shares of the company’s stock worth $85,000 after acquiring an additional 3,878 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new position in Cartesian Therapeutics during the fourth quarter valued at $112,000. Jain Global LLC acquired a new stake in shares of Cartesian Therapeutics in the fourth quarter valued at about $121,000. Squarepoint Ops LLC purchased a new stake in shares of Cartesian Therapeutics during the fourth quarter worth about $131,000. Finally, Bank of America Corp DE raised its position in shares of Cartesian Therapeutics by 133.0% during the 2nd quarter. Bank of America Corp DE now owns 13,933 shares of the company’s stock worth $145,000 after purchasing an additional 7,952 shares during the last quarter. 86.95% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

RNAC has been the subject of several research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cartesian Therapeutics in a research note on Monday, December 29th. Wedbush restated an “outperform” rating and issued a $38.00 target price on shares of Cartesian Therapeutics in a research note on Tuesday. HC Wainwright lowered their price target on Cartesian Therapeutics from $40.00 to $30.00 and set a “buy” rating for the company in a research report on Wednesday, November 19th. Cantor Fitzgerald raised Cartesian Therapeutics from a “neutral” rating to an “overweight” rating and set a $16.00 price objective on the stock in a report on Monday. Finally, Needham & Company LLC restated a “buy” rating and issued a $42.00 price objective on shares of Cartesian Therapeutics in a research note on Monday. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $34.00.

Trending Headlines about Cartesian Therapeutics

Here are the key news stories impacting Cartesian Therapeutics this week:

• Positive Sentiment: Several brokerages reiterated/upgraded coverage and set substantially higher price targets — Wedbush reaffirmed an “outperform” rating with a $38 target and Needham reiterated a “buy” with a $42 target, both implying large upside versus current levels. Analyst optimism can support buying interest and underpin the rally in RNAC shares. Benzinga
• Positive Sentiment: Cantor Fitzgerald upgraded Cartesian from “neutral” to “overweight” (new $16 price target) — a separate report/summary on the upgrade is available via MSN. Upgrades from institutional research teams often attract momentum buying and increase investor visibility. Cantor Fitzgerald upgrade (MSN)
• Neutral Sentiment: Company issued a full-year 2025 financial report and business update; the filing contains operational and guidance details that investors will parse for pipeline progress and cash runway. The update is a mixed-context item whose impact depends on specific program milestones and guidance. Business Insider
• Neutral Sentiment: Short-interest reporting shows effectively zero reported short interest for early March, though the published figures appear anomalous (NaN/zero), so short-squeeze dynamics are unlikely to be a clear driver based on this data alone.
• Negative Sentiment: Recent quarterly results included a large EPS miss: the company reported ($3.57) EPS vs. consensus (~$0.82 loss), although revenue modestly exceeded expectations. The sizable earnings shortfall increases near-term downside risk as investors reassess cash burn, funding needs, and timeline for clinical progress. Earnings / MarketBeat

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, trading on NASDAQ under the symbol RNAC, is a clinical‐stage biotechnology company specializing in the development of messenger RNA (mRNA)-based therapeutics. The company leverages a proprietary RNA delivery platform to induce the production of therapeutic proteins within patients, aiming to address a range of diseases through in vivo expression of disease-modifying agents. Cartesian’s technology is designed to optimize mRNA stability, translation efficiency and targeted delivery, with potential applications spanning oncology, autoimmune disorders and rare genetic conditions.

At the core of Cartesian’s approach is a synthetic mRNA platform that incorporates proprietary lipid nanoparticle (LNP) formulations.